The FDA's recent move was a giant step toward a calamitous new drug approval policy.

Patients would be better off if the FDA focused on unearthing information to help doctors determine which pills will perform the best for each individual patient.

Patients would benefit greatly if the Food and Drug Administration let doctors make decisions for patients based on individual needs.

It would be too easy, in an effort to cut costs, to constrict the pipeline that is producing one new wonder drug after another.

New research findings and a thorough reassessment of older research indicate that drugs like Vioxx can have many important benefits and great potential for addressing serious problems.

Post-approval drug safety surveillance is an extraordinarily difficult task.The Vioxx episode has probably made it more difficult for the Food and Drug Administration to do its job.

Bill Clinton's proposed drug benefit for Medicare recipients is predicated on driving down the cost of drugs that elderly Americans need.

We have a pharmaceutical research and development system that really works.